Switch theme
Sign up to access all valuation multiples
Burjeel Holdings PLC is a healthcare service provider. Along with its subsidiaries, it provides multi-specialty hospitals, medical, surgical and dental services, and the sale of pharmaceutical goods and medical equipment. The group's reportable segments are Hospitals, Medical Centre, Pharmacies, and Others. Maximum revenue for the group is derived from the Hospitals segment, which includes entities that provide inpatient, day-care services, and outpatient services to patients to diagnosis the disease and offer medical and surgical treatment as part of in-patient services. Geographically, it derives maximum revenue from its customers in the United Arab Emirates, followed by the Sultanate of Oman and the Kingdom of Saudi Arabia.
2020
12.3K+
LTM Revenue $1.4B
LTM EBITDA $277M
$2.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Burjeel Holdings has a last 12-month revenue (LTM) of $1.4B and a last 12-month EBITDA of $277M.
In the most recent fiscal year, Burjeel Holdings achieved revenue of $1.3B and an EBITDA of $247M.
Burjeel Holdings expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Burjeel Holdings valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.4B | XXX | $1.3B | XXX | XXX | XXX |
| Gross Profit | $1.4B | XXX | $403M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 30% | XXX | XXX | XXX |
| EBITDA | $277M | XXX | $247M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| EBIT | n/a | XXX | $146M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $123M | XXX | $94.6M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $265M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Burjeel Holdings's stock price is AED 1 (or $0).
Burjeel Holdings has current market cap of AED 7.4B (or $2.0B), and EV of AED 9.9B (or $2.7B).
See Burjeel Holdings trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.7B | $2.0B | XXX | XXX | XXX | XXX | $0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Burjeel Holdings has market cap of $2.0B and EV of $2.7B.
Burjeel Holdings's trades at 2.0x EV/Revenue multiple, and 11.0x EV/EBITDA.
Equity research analysts estimate Burjeel Holdings's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Burjeel Holdings has a P/E ratio of 16.4x.
See valuation multiples for Burjeel Holdings and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EV (current) | $2.7B | XXX | $2.7B | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 9.7x | XXX | 11.0x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 18.5x | XXX | XXX | XXX |
| EV/Gross Profit | 1.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 16.4x | XXX | 21.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 40.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBurjeel Holdings's last 12 month revenue growth is 10%
Burjeel Holdings's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $21K for the same period.
Burjeel Holdings's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Burjeel Holdings's rule of X is 45% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Burjeel Holdings and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | 7% | XXX | XXX | XXX |
| Rule of 40 | 33% | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 45% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $21K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Athens Medical Centre | XXX | XXX | XXX | XXX | XXX | XXX |
| Compass Pathways | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Burjeel Holdings acquired XXX companies to date.
Last acquisition by Burjeel Holdings was XXXXXXXX, XXXXX XXXXX XXXXXX . Burjeel Holdings acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Burjeel Holdings founded? | Burjeel Holdings was founded in 2020. |
| Where is Burjeel Holdings headquartered? | Burjeel Holdings is headquartered in United Arab Emirates. |
| How many employees does Burjeel Holdings have? | As of today, Burjeel Holdings has 12.3K+ employees. |
| Is Burjeel Holdings publicy listed? | Yes, Burjeel Holdings is a public company listed on ADS. |
| What is the stock symbol of Burjeel Holdings? | Burjeel Holdings trades under BURJEEL ticker. |
| When did Burjeel Holdings go public? | Burjeel Holdings went public in 2022. |
| Who are competitors of Burjeel Holdings? | Similar companies to Burjeel Holdings include e.g. PureHealth, Integral Diagnostics, Ramsay Health, Athens Medical Centre. |
| What is the current market cap of Burjeel Holdings? | Burjeel Holdings's current market cap is $2.0B |
| What is the current revenue of Burjeel Holdings? | Burjeel Holdings's last 12 months revenue is $1.4B. |
| What is the current revenue growth of Burjeel Holdings? | Burjeel Holdings revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Burjeel Holdings? | Current revenue multiple of Burjeel Holdings is 1.9x. |
| Is Burjeel Holdings profitable? | Yes, Burjeel Holdings is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Burjeel Holdings? | Burjeel Holdings's last 12 months EBITDA is $277M. |
| What is Burjeel Holdings's EBITDA margin? | Burjeel Holdings's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Burjeel Holdings? | Current EBITDA multiple of Burjeel Holdings is 9.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
